C-265At second reading in the House of Commons

Law Would Speed Up Access to Unapproved Medicines

Faster Access to Medicines

Introduced Mar 11, 2026·Last discussed Mar 19, 2026

Summary

This proposed law aims to change how Canadians can access drugs that aren't yet approved for sale in Canada. It would create a list of drugs that are pre-approved for special access. Doctors could then request these drugs for their patients more easily, especially for serious or life-threatening conditions when no other suitable treatment is available. This change would mostly affect patients with serious illnesses, rare diseases, or those who have exhausted other treatment options. It would also affect doctors, pharmacists, hospitals, and drug companies. The government would create a committee of experts to help decide which drugs should be on the list. The government would also track how these drugs are used and make sure they are safe. This matters because it could give patients access to potentially life-saving treatments sooner. It could also give doctors more options when treating complex or rare conditions. The proposed law also aims to ensure that the process is safe and transparent, with the government monitoring the use of these drugs and making information available to the public.

Where This Lands on Key Issues

Where this proposed law falls on the policy spectrums that Canadians care about

HealthcareExpand public coverage (dental, pharma)

The bill expands access to drugs not yet approved in Canada, which could be seen as a step towards expanding healthcare options, though it doesn't directly address funding or universal access.

Drug PolicyDecriminalize and treat as health issue

By making it easier for doctors to prescribe unapproved drugs, the bill shifts away from strict regulation and control of pharmaceuticals, aligning with a more health-focused approach to drug access.

This bill

Bill Quality

Solid

This proposed law creates a list of pre-approved, non-marketed drugs for serious conditions when no other option exists in Canada. It aims to give doctors faster access to needed treatments, but relies heavily on the Minister's discretion and future regulations.

Things to Watch For

The law does not specify how the expert advisory committee will be selected.
It's unclear how cost will be managed, potentially limiting access based on price.
The Minister has broad power to remove drugs from the list, which could change treatment options quickly.
The law does not address how patients can learn about available drugs on the list.
The law does not guarantee manufacturers will supply the drugs, even if requested.
The law does not include a process for patients to appeal if a drug is not added to the list or is removed.

Progress

Click any step to learn what it means